Action RV6 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Charles River Laboratories International, Inc. Deutsche Boerse AG

Actions

RV6

US1598641074

Marché Fermé - Deutsche Boerse AG
Autres places de cotation
 08:07:56 10/05/2024 		Varia. 5j. Varia. 1 janv.
212,9 EUR -2,38% Graphique intraday de Charles River Laboratories International, Inc. -0,42% -0,56%
10/05 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. : JPMorgan Chase est neutre sur le titre ZM
10/05 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. : Jefferies & Co. toujours positif ZM

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Charles River Laboratories International Q1 Non-GAAP Earnings Rise, Revenue Fall; Maintains Full Year 2024 Earnings Guidance
Charles River Laboratories International, Inc. Reports Impairment Charges for the First Quarter Ended March 30, 2024
Charles River Laboratories International, Inc. Reports Earnings Results for the First Quarter Ended March 30, 2024
Earnings Flash (CRL) CHARLES RIVER LABORATORIES INTERNATIONAL Reports Q1 Adjusted EPS $2.27
Stocks Down Pre-Bell Ahead of Latest Earnings Results; Asia, Europe Churn
Earnings Flash (CRL) CHARLES RIVER LABORATORIES INTERNATIONAL Posts Q1 Revenue $1.01B
(CRL) CHARLES RIVER LABORATORIES INTERNATIONAL Expects Fiscal Year 2024 Adjusted EPS Range $10.90 - $11.40
Charles River: Q1 Earnings Snapshot
Charles River Laboratories Announces First-Quarter 2024 Results
Charles River Laboratories International, Inc. Revises Financial Guidance for 2024
China trade heats up, UK rates in view
Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
FibroBiologics, Inc. Plans to Collaborate with Charles River Laboratories to Manufacture Fibroblast-Based Spheroids
Charles River Laboratories International : Proxy Supplement Filed April 24, 2024
Charles River Laboratories Files Supplement to Definitive Proxy Statement with the Securities and Exchange Commission
Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
Charles River Laboratories International : 2023 Corporate Citizenship Report
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action CRL
  4. Action RV6
  5. Actualités Charles River Laboratories International, Inc.
  6. Autres langues